Literature DB >> 22628233

New sandwich-type enzyme-linked immunosorbent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection.

Mizuho Kawamura1, Akira Kusano, Akiko Furuya, Nobuo Hanai, Hideki Tanigaki, Akihito Tomita, Akira Horiguchi, Kyosuke Nagata, Toshiko Itazawa, Yuichi Adachi, Yoshie Okabe, Toshio Miyawaki, Hiroaki Kohno.   

Abstract

OBJECTIVES: To develop a clinically significant and practical enzyme-linked immunosorbent assay (ELISA) for the detection of MxA protein in human whole blood, a biological marker of viral infection. DESIGN AND METHODS: A sandwich ELISA suitable for the measurement of human MxA protein in whole blood was developed using mouse monoclonal antibodies (mAbs) raised against the GTP-binding domain of human MxA protein. Prior to the assay, the whole blood sample was treated with special buffer to extract the MxA protein, improve its stability, and avoid interference from hemoglobin.
RESULTS: This ELISA meets all the requirements for use in routine clinical assays, especially in terms of sensitivity (detection limit: 1.3 ng/ml whole blood), accuracy (recovery: 93.0-100.0%), and rapidity (<1.5 h). The present ELISA had a sensitivity of 100% and a specificity of 100% for viral infection when compared to samples from healthy control and 87.1% and 90.9% when compared to samples from the bacterial infection group.
CONCLUSION: We have developed a new ELISA for measuring MxA protein in human whole blood using mAbs specific for the GTP-binding domain of MxA. This ELISA has analytical performance enough for routine clinical assay and can be used in detecting the possibility of viral infection.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628233      PMCID: PMC6807620          DOI: 10.1002/jcla.21507

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  28 in total

1.  Control of IFN-inducible MxA gene expression in human cells.

Authors:  T Ronni; K Melén; A Malygin; I Julkunen
Journal:  J Immunol       Date:  1993-03-01       Impact factor: 5.422

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Inhibition of coxsackievirus B4 replication in stably transfected cells expressing human MxA protein.

Authors:  V Chieux; W Chehadeh; J Harvey; O Haller; P Wattré; D Hober
Journal:  Virology       Date:  2001-04-25       Impact factor: 3.616

4.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

5.  MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha.

Authors:  V Meier; S Mihm; G Ramadori
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

6.  Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins.

Authors:  M A Horisberger
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Expression of MxA protein in blood lymphocytes discriminates between viral and bacterial infections in febrile children.

Authors:  M Halminen; J Ilonen; I Julkunen; O Ruuskanen; O Simell; M J Mäkelä
Journal:  Pediatr Res       Date:  1997-05       Impact factor: 3.756

8.  MxA-dependent inhibition of measles virus glycoprotein synthesis in a stably transfected human monocytic cell line.

Authors:  J J Schnorr; S Schneider-Schaulies; A Simon-Jödicke; J Pavlovic; M A Horisberger; V ter Meulen
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

9.  Outpatient management without antibiotics of fever in selected infants.

Authors:  M D Baker; L M Bell; J R Avner
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

10.  Febrile infants at low risk for serious bacterial infection--an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group.

Authors:  J A Jaskiewicz; C A McCarthy; A C Richardson; K C White; D J Fisher; R Dagan; K R Powell
Journal:  Pediatrics       Date:  1994-09       Impact factor: 7.124

View more
  7 in total

1.  Ultrafast Electrothermal Flow-Enhanced Magneto Biosensor for Highly Sensitive Protein Detection in Whole Blood.

Authors:  Jiran Li; Peter B Lillehoj
Journal:  Angew Chem Int Ed Engl       Date:  2022-03-30       Impact factor: 16.823

Review 2.  Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review.

Authors:  Anokhi J Kapasi; Sabine Dittrich; Iveth J González; Timothy C Rodwell
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

Review 3.  Virus-induced secondary bacterial infection: a concise review.

Authors:  Mohamed A Hendaus; Fatima A Jomha; Ahmed H Alhammadi
Journal:  Ther Clin Risk Manag       Date:  2015-08-24       Impact factor: 2.423

4.  Evaluation of a combined MxA and CRP point-of-care immunoassay to identify viral and/or bacterial immune response in patients with acute febrile respiratory infection.

Authors:  Robert Sambursky; Nathan Shapiro
Journal:  Eur Clin Respir J       Date:  2015-12-10

5.  Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use.

Authors:  Patrick Joseph; Eliot Godofsky
Journal:  Open Forum Infect Dis       Date:  2018-02-15       Impact factor: 3.835

6.  Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections.

Authors:  Wesley H Self; Jeffrey Rosen; Stephan C Sharp; Michael R Filbin; Peter C Hou; Amisha D Parekh; Michael C Kurz; Nathan I Shapiro
Journal:  J Clin Med       Date:  2017-10-07       Impact factor: 4.241

7.  Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic.

Authors:  Michael S Pulia; Terrence P O'Brien; Peter C Hou; Andrew Schuman; Robert Sambursky
Journal:  Ann Med       Date:  2020-05-14       Impact factor: 4.709

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.